Custom Organic Compound Synthesis (Non-GMP)

The contract involves the custom synthesis of five small-molecule compounds, each in quantities of five grams, for use in Ewing sarcoma drug development under non-GMP research conditions. The work encompasses the full scope of organic synthesis including route design, multi-step chemical reactions, and purification to yield chemically defined products suitable for preclinical evaluation. All activities are non-GMP, meaning the compounds will not be produced under regulatory quality systems required for clinical use but rather for internal research and biological testing purposes. The effort is structured as a subcontract under the National Institutes of Health, operating through the Department of Health and Human Services, with the NAICS code 325412 indicating pharmaceutical and medicine manufacturing. The solicitation was posted on August 7, 2026, and responses are due by August 24, 2026, with no set-aside designation applied. The place of performance and point of contact details are not specified, and the work is expected to be carried out by an external research or synthesis provider aligned with the NIH’s oncology drug discovery goals.